Numerous clinical trials ranging from Early Phase 1 through Phase 4 evaluate Plerixafor (AMD3100), with recruitment statuses spanning recruiting, active, completed, terminated, and withdrawn. Sponsored by academic institutions, research foundations, and pharmaceutical companies, these studies primarily focus on stem cell mobilization and hematologic malignancies including multiple myeloma, non-Hodgkin lymphoma, and chronic lymphocytic leukemia. Research also encompasses stem cell transplant complications, sickle cell disease, COVID-19 respiratory distress, wound repair, and gynecologic conditions.
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT06851767 | ENROLLING_BY_INVITATION | X-linked Severe Combined Immunodeficiency; X-SCID; XSCID |
National Institute of Allergy and Infectious Diseases (NIAID) |
2025-05-09 | PHASE1; PHASE2 |
| NCT06325709 | RECRUITING | Chronic Granulomatous Disease (CGD); X-Linked Chronic Granulomatous Disease |
National Institute of Allergy and Infectious Diseases (NIAID) |
2024-04-17 | PHASE1; PHASE2 |
| NCT07605416 | RECRUITING | Plasma Cell Leukemia |
National Cancer Institute (NCI) |
2027-04-20 | PHASE2 |
| NCT07775313 | NOT_YET_RECRUITING | WHIM; Warts; Hypogammaglobulinemia; Immunodeficiency; Myelokathexis |
National Institute of Allergy and Infectious Diseases (NIAID) |
2026-09-09 | PHASE1; PHASE2 |
| NCT02015013 | RECRUITING | Idiopathic CD4-Positive; T-Lymphocytopenia |
National Institute of Allergy and Infectious Diseases (NIAID) |
2014-01-15 | PHASE2 |
| NCT06872333 | RECRUITING | Graft Failure; Sickle Cell Disease; Hemoglobinopathies |
Masonic Cancer Center, University of Minnesota |
2024-11-19 | PHASE2 |
| NCT06207799 | RECRUITING | Multiple Myeloma; Post-transplant MRD-guided Maintenance Therapy; Pre-transplant Purging |
M.D. Anderson Cancer Center |
2024-07-17 | PHASE2 |
| NCT06506461 | RECRUITING | Sickle Cell Disease |
St. Jude Children's Research Hospital |
2025-03-21 | PHASE1 |
| NCT07585136 | NOT_YET_RECRUITING | Bone Marrow Failure Syndrome |
St. Jude Children's Research Hospital |
2026-11 | PHASE1 |
| NCT06158828 | RECRUITING | AML, Childhood; Aml; Acute Myeloid Leukemia, Pediatric; Acute Myeloid Leukemia |
Washington University School of Medicine |
2024-11-15 | PHASE1; PHASE2 |
| NCT05088356 | ACTIVE_NOT_RECRUITING | Allogeneic Hematopoietic Cell Transplantation (HCT); Advanced Hematologic Malignancies; Acute Leukemia; Chronic Myelogenous Leukemia; Myelodysplastic Syndromes; Myeloproliferative Disorders |
Stanford University |
2021-09-07 | PHASE1 |
| NCT07188090 | RECRUITING | Multiple Myeloma; Hodgkin Lymphoma; Non-hodgkin Lymphoma |
Thomas Jefferson University |
2025-10-16 | PHASE2 |
| NCT07341022 | NOT_YET_RECRUITING | Sickle Cell Disease |
Hospital Israelita Albert Einstein |
2026-06-01 | PHASE1; PHASE2 |
| NCT05470491 | RECRUITING | HIV; Hematologic Malignancies |
National Cancer Institute (NCI) |
2023-01-26 | PHASE1; PHASE2 |
| NCT03664830 | ACTIVE_NOT_RECRUITING | Sickle Cell Disease |
City of Hope Medical Center |
2018-09-19 | PHASE1 |
| NCT06414889 | RECRUITING | RUNX1 Familial Platelet Disorder |
M.D. Anderson Cancer Center |
2024-05-20 | PHASE1 |
| NCT05343572 | RECRUITING | Asherman Syndrome; Atrophic Endometrium; Recurrent Implantation Failure |
Hugh Taylor |
2023-11-01 | EARLY_PHASE1 |
| NCT02570542 | ACTIVE_NOT_RECRUITING | Diffuse Large B-cell Lymphoma (DLBCL); Relapsed Diffuse Large B-cell Lymphoma (DLBCL); Refractory Diffuse Large B-cell Lymphoma (DLBCL) |
Memorial Sloan Kettering Cancer Center |
2015-10 | PHASE2 |
| NCT04362293 | ACTIVE_NOT_RECRUITING | Sickle Cell Disease |
St. Jude Children's Research Hospital |
2020-04-30 | PHASE2 |
| NCT05357482 | ACTIVE_NOT_RECRUITING | Sickle Cell Anemia; Beta Thalassemia |
National Heart, Lung, and Blood Institute (NHLBI) |
2022-05-12 | PHASE1; PHASE2 |
| NCT03653247 | COMPLETED | Sickle Cell Disease |
Sangamo Therapeutics |
2019-03-06 | PHASE1; PHASE2 |
| NCT02193191 | COMPLETED | Sickle Cell Disease |
Memorial Sloan Kettering Cancer Center |
2014-09-17 | PHASE1 |
| NCT06141304 | UNKNOWN | Relapsed Adult ALL; Relapsed Adult AML |
The First Hospital of Jilin University |
2023-09-01 | PHASE2 |
| NCT01526096 | COMPLETED | Myeloma |
University of Chicago |
2011-07-12 | PHASE1 |
| NCT03182426 | COMPLETED | Diabetes Mellitus, Type 1 |
University of Alberta |
2017-08-15 | PHASE1; PHASE2 |
| NCT05421416 | Not yet recruiting | Stem Cell Transplant Complications |
AHS Cancer Control Alberta |
2024-04-01 | Phase 2 |
| NCT01331018 | TERMINATED | Fanconi Anemia |
Fred Hutchinson Cancer Center |
2012-02-22 | PHASE1 |
| NCT05510544 | UNKNOWN | Lymphoma |
Peking University |
2022-12-19 | PHASE4 |
| NCT05343572 | Recruiting | Asherman Syndrome|Atrophic Endometrium|Recurrent Implantation Failure |
Hugh Taylor|Yale University |
2023-11-01 | Early Phase 1 |
| NCT05844527 | Recruiting | Wound of Skin|Abdominal Wound |
MedRegen LLC |
2023-11-20 | Phase 2 |
| NCT03240861 | TERMINATED | HLA-A*0201 Positive Cells Present; Locally Advanced Malignant Neoplasm; NY-ESO-1 Positive; Unresectable Malignant Neoplasm; Sarcoma |
Jonsson Comprehensive Cancer Center |
2017-07-26 | PHASE1 |
| NCT01413100 | COMPLETED | Systemic Scleroderma |
Fred Hutchinson Cancer Center |
2011-09-15 | PHASE2 |
| NCT03055247 | RECRUITING | Chronic Granulomatous Disease X-linked (X-CGD) |
IRCCS San Raffaele |
2015-11-06 | PHASE2 |
| NCT04817345 | WITHDRAWN | Sickle Cell Disease |
St. Jude Children's Research Hospital |
2023-04 | PHASE2 |
| NCT04177810 | COMPLETED | Metastatic Pancreatic Cancer |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
2020-11-16 | PHASE2 |
| NCT03547830 | UNKNOWN | Chronic Granulomatous Disease |
Federal Research Institute of Pediatric Hematology, Oncology and Immunology |
2019-04-13 | PHASE2 |
| NCT05445128 | TERMINATED | Sickle Cell Disease |
Ensoma |
2022-06-24 | PHASE2 |
| NCT05087212 | COMPLETED | Autologous Haematopoietic Stem Cell Transplant |
Sanofi |
2021-10-22 | PHASE4 |
| NCT05007652 | COMPLETED | Multiple Myeloma and Malignant Lymphoma |
Kyowa Kirin Co., Ltd. |
2021-09-01 | PHASE2 |
| NCT05411575 | WITHDRAWN | COVID-19 Acute Respiratory Distress Syndrome; COVID-19 |
4Living Biotech |
2022-07-19 | PHASE2 |
| NCT05411575 | Withdrawn | COVID-19 Acute Respiratory Distress Syndrome|COVID-19 |
4Living Biotech|4P-Pharma |
2022-07-19 | Phase 2 |
| NCT05445128 | Terminated | Sickle Cell Disease |
Ensoma|bluebird bio |
2022-06-24 | Phase 2 |
| NCT03746080 | COMPLETED | Glioblastoma; Glioblastoma With Primitive Neuronal Component; Gliosarcoma; Malignant Glioma; Oligodendroglial Component Present |
Lawrence D Recht |
2018-12-04 | PHASE2 |
| NCT05835726 | Recruiting | Multiple Myeloma|Autologous Stem Cell Transplantation|Leukapheresis |
Fondazione Policlinico Universitario Agostino Gemelli IRCCS |
2022-01-01 | -- |
| NCT04762875 | TERMINATED | Related Donors Donating PBSC to a Family Member; Healthy Donors; Acute Myelogenous Leukemia; Acute Lymphoblastic Leukemia; Myelodysplastic Syndrome |
Ensoma |
2021-06-16 | PHASE2 |
| NCT04552743 | COMPLETED | Multiple Myeloma |
Surbhi Sidana, MD |
2020-10-05 | PHASE2 |
| NCT03317899 | COMPLETED | Non-Hodgkin's Lymphoma; Plasma Cell Myeloma |
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University |
2017-10-12 | PHASE2 |
| NCT04045821 | TERMINATED | Infertility of Uterine Origin |
Reproductive Medicine Associates of New Jersey |
2020-01-17 | |
| NCT06892119 | COMPLETED | Lymphoma; Myeloma |
Hospital Universitario Dr. Jose E. Gonzalez |
2019-12-09 | PHASE1 |
| NCT02231879 | COMPLETED | Myelokathexis; Infections; Neutropenia; Warts; Hypogammaglobulinemia |
National Institute of Allergy and Infectious Diseases (NIAID) |
2014-10-14 | PHASE2; PHASE3 |
| NCT02522572 | UNKNOWN | Transplants and Implants |
E. Steve Woodle |
2015-08 | PHASE1; PHASE2 |
| NCT02343666 | WITHDRAWN | Human Immunodeficiency Virus 1 Positive; Stage I Adult Hodgkin Lymphoma; Stage I Adult Non-Hodgkin Lymphoma; Stage II Adult Hodgkin Lymphoma; Stage II Adult Non-Hodgkin Lymphoma; Stage III Adult Hodgkin Lymphoma; Stage III Adult Non-Hodgkin Lymphoma; Stage IV Adult Hodgkin Lymphoma; Stage IV Adult Non-Hodgkin Lymphoma |
Fred Hutchinson Cancer Center |
2016-08-15 | PHASE1 |
| NCT03932864 | COMPLETED | Healthy Volunteers |
Ensoma |
2019-04-22 | PHASE1 |
| NCT03277209 | TERMINATED | Pancreas Cancer |
Weill Medical College of Cornell University |
2017-07-25 | PHASE1 |
| NCT04058145 | WITHDRAWN | Head and Neck Cancer |
Massachusetts General Hospital |
2019-09-30 | PHASE2 |
| NCT02790957 | TERMINATED | Diabetes; Wounds; Critical Limb Ischemia |
Gian Paolo Fadini |
2016-06 | PHASE2 |
| NCT03506802 | WITHDRAWN | HLA-A*0201 Positive Cells Present; NY-ESO-1 Positive Tumor Cells Present; Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma |
Jonsson Comprehensive Cancer Center |
2018-07-10 | PHASE1 |
| NCT03157804 | COMPLETED | Fanconi Anemia |
Hospital Infantil Universitario Niño Jesús, Madrid, Spain |
2016-01-07 | PHASE1; PHASE2 |
| NCT03226691 | COMPLETED | Sickle Cell Disease |
National Heart, Lung, and Blood Institute (NHLBI) |
2017-07-25 | PHASE1 |
| NCT01146834 | COMPLETED | Multiple Myeloma |
Weill Medical College of Cornell University |
2011-03 | PHASE3 |
| NCT02006225 | UNKNOWN | Autologous Stem Cell Transplantation |
Tel-Aviv Sourasky Medical Center |
2014-02 | PHASE4 |
| NCT02179970 | COMPLETED | Pancreatic Adenocarcinoma Metastatic; Ovarian Serous Adenocarcinoma; Colorectal Cancer Metastatic |
CCTU- Cancer Theme |
2015-06 | PHASE1 |
| NCT03019809 | UNKNOWN | Wiskott-Aldrich Syndrome; Hematopoietic Stem Cell Transplantation; Graft Failure |
Federal Research Institute of Pediatric Hematology, Oncology and Immunology |
2016-06 | PHASE2 |
| NCT02678533 | COMPLETED | Fanconi Anemia |
Assistance Publique - Hôpitaux de Paris |
2017-02-10 | PHASE1; PHASE2 |
| NCT02931071 | COMPLETED | Fanconi Anemia |
Hospital Universitari Vall d'Hebron Research Institute |
2013-09 | PHASE2 |
| NCT02069080 | TERMINATED | Cancer |
National Institute of Allergy and Infectious Diseases (NIAID) |
2014-02-20 | EARLY_PHASE1 |
| NCT00669669 | TERMINATED | Glioblastoma; Gliosarcoma |
Fred Hutchinson Cancer Center |
2009-02-25 | PHASE1; PHASE2 |
| NCT03244930 | UNKNOWN | Lymphoma, Non-Hodgkin; Lymphoma, Hodgkin; Myeloma; Stem Cell Transplant Complications |
Hospital Universitario Dr. Jose E. Gonzalez |
2017-05-10 | PHASE2 |
| NCT02989701 | COMPLETED | Sickle Cell Disease Without Crisis |
Alessandra Biffi |
2017-01 | PHASE1 |
| NCT01977677 | COMPLETED | Adult Ependymoblastoma; Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Adult Medulloblastoma; Adult Mixed Glioma; Adult Oligodendroglial Tumors; Adult Pineoblastoma; Adult Supratentorial Primitive Neuroectodermal Tumor (PNET) |
Lawrence Recht |
2014-11 | PHASE1; PHASE2 |
| NCT01916577 | COMPLETED | COPD; Cystic Fibrosis; Pulmonary Fibrosis |
University of Colorado, Denver |
2013-08 | PHASE1 |
| NCT01288573 | COMPLETED | Ewing's Sarcoma/Soft Tissue Sarcoma; Neuroblastoma; Brain Tumors |
Genzyme, a Sanofi Company |
2014-03-03 | PHASE1; PHASE2 |
| NCT02212535 | COMPLETED | Major Sickle Cell Syndrome of Type SS or Sβ Thalassemia |
Assistance Publique - Hôpitaux de Paris |
2016-01-15 | PHASE1; PHASE2 |
| NCT00943943 | COMPLETED | Acute Myelogenous Leukemia; Leukemia |
M.D. Anderson Cancer Center |
2010-10-29 | PHASE1 |
| NCT02682953 | WITHDRAWN | Bone Marrow Transplantation; Hematopoietic Stem Cells; Multiple Myeloma; Lymphoma |
University of Maryland, Baltimore |
2015-10 | PHASE2 |
| NCT01352650 | COMPLETED | Acute Myeloid Leukemia |
Weill Medical College of Cornell University |
2011-06-17 | PHASE1 |
| NCT01753453 | COMPLETED | Multiple Myeloma |
Sanofi |
2013-06 | PHASE2 |
| NCT01696461 | COMPLETED | Related Donors Donating Peripheral Blood Stem Cells (PBSC) to a Family Member; Acute Myelogenous Leukemia; Acute Lymphoblastic Leukemia; Myelodysplastic Syndrome; Chronic Myelogenous Leukemia; Non-Hodgkin's Lymphoma; Hodgkin's Disease; Chronic Lymphocytic Leukemia |
Center for International Blood and Marrow Transplant Research |
2013-05 | PHASE2 |
| NCT02098109 | COMPLETED | Multiple Myeloma; Lymphoma, Non-Hodgkin |
Washington University School of Medicine |
2014-08-20 | PHASE2 |
| NCT01818284 | COMPLETED | Blood And Marrow Transplantation |
M.D. Anderson Cancer Center |
2013-10 | PHASE2 |
| NCT00903968 | COMPLETED | Multiple Myeloma |
Dana-Farber Cancer Institute |
2009-06-01 | PHASE1; PHASE2 |
| NCT01435343 | COMPLETED | Acute Myeloblastic Leukemia |
PETHEMA Foundation |
2012-07 | PHASE1; PHASE2 |
| NCT01408043 | TERMINATED | Adult Acute Lymphoblastic Leukemia in Remission; Adult Grade III Lymphomatoid Granulomatosis; Adult Nasal Type Extranodal NK/T-cell Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Cutaneous B-cell Non-Hodgkin Lymphoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Hepatosplenic T-cell Lymphoma; Nodal Marginal Zone B-cell Lymphoma; Noncutaneous Extranodal Lymphoma; Peripheral T-cell Lymphoma; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Adult T-cell Leukemia/Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Hairy Cell Leukemia; Small Intestine Lymphoma; Splenic Marginal Zone Lymphoma; T-cell Large Granular Lymphocyte Leukemia; Testicular Lymphoma; Waldenström Macroglobulinemia |
Case Comprehensive Cancer Center |
2011-10 | |
| NCT02221492 | COMPLETED | Lymphoma |
Genzyme, a Sanofi Company |
2014-11 | PHASE2 |
| NCT02200380 | TERMINATED | For Donors; Related Donors Giving Peripheral Blood Stem Cells (PBSC) to a Sibling; For Recipients; Acute Myelogenous Leukemia (AML); Acute Lymphoblastic Leukemia (ALL); Myelodysplastic Syndrome (MDS); Chronic Myelogenous Leukemia (CML); Non-Hodgkins Lymphoma (NHL); Hodgkins Disease (HD); Chronic Lymphocytic Leukemia (CLL) |
Celldex Therapeutics |
2014-07 | PHASE2 |
| NCT01160354 | TERMINATED | Acute Myelogenous Leukemia |
M.D. Anderson Cancer Center |
2010-08 | PHASE1; PHASE2 |
| NCT01353937 | WITHDRAWN | Diabetic Ulcer |
NYU Langone Health |
2014-04 | PHASE1 |
| NCT01954914 | COMPLETED | Blood Stem Cell Harvest Failure |
Technische Universität Dresden |
2013-12 | PHASE2 |
| NCT01621477 | TERMINATED | Acute Lymphoblastic Leukemia; Acute Myelocytic Leukemia; Chronic Myelocytic Leukemia; Juvenile Myelomonocytic Leukemia; Myelodysplastic Syndrome; Hodgkin or Non-Hodgkin Lymphoma; Sarcoma, Myeloid |
St. Jude Children's Research Hospital |
2012-08 | PHASE2 |
| NCT01403896 | COMPLETED | Malignant Lymphoma, Stem Cell Type |
Stephen Couban |
2012-04 | PHASE2 |
| NCT01339572 | COMPLETED | Non-Hodgkin's Lymphoma; Multiple Myeloma |
University of Florida |
2011-04 | PHASE2 |
| NCT02221479 | COMPLETED | Multiple Myeloma |
Genzyme, a Sanofi Company |
2014-10 | PHASE2 |
| NCT01186224 | COMPLETED | Multiple Myeloma; Plasma Cell Dyscrasia; Lymphoma; Lymphoproliferative Disorders |
University of Liverpool |
2010-05 | |
| NCT01164345 | COMPLETED | Non-Hodgkin's Lymphoma; Hodgkin's Lymphoma; Stem Cell Mobilization; Autologous Stem Cell Transplantation |
Sheba Medical Center |
2010-06 | PHASE2 |
| NCT01455025 | TERMINATED | Acute Myeloid Leukemia |
French Innovative Leukemia Organisation |
2012-01 | PHASE1 |
| NCT00322127 | COMPLETED | Healthy Volunteers |
National Heart, Lung, and Blood Institute (NHLBI) |
2006-06-14 | PHASE1 |
| NCT01767714 | COMPLETED | Non-Hodgkin's Lymphoma |
Sanofi |
2013-04 | PHASE3 |
| NCT01746173 | TERMINATED | T-cell Non-Hodgkin Lymphoma |
Dana-Farber Cancer Institute |
2013-07 | PHASE2 |
| NCT02056210 | COMPLETED | Diabetes |
University of Padova |
2014-02 | PHASE4 |
| NCT01280955 | COMPLETED | Failure of Bone Marrow Graft |
Mitchell Horwitz, MD |
2011-12 | PHASE1; PHASE2 |
| NCT01065129 | COMPLETED | Myelodysplastic Syndromes |
Washington University School of Medicine |
2010-09-02 | PHASE1 |
| NCT01547806 | COMPLETED | Plasma Cell Myeloma; Multiple Myeloma |
National Cancer Institute (NCI) |
2012-02-22 | PHASE2 |
| NCT01610999 | TERMINATED | Chronic Lymphocytic Leukemia; Lymphoma; Multiple Myeloma |
Tufts Medical Center |
2013-07 | PHASE1 |
| NCT01026987 | COMPLETED | Stem Cell Transplant Patients |
Washington University School of Medicine |
2010-04-29 | PHASE1 |
| NCT01339039 | TERMINATED | High Grade Glioma: Glioblastoma (GBM); High Grade Glioma: Gliosarcoma; Anaplastic Astrocytoma (AA); Anaplastic Oligodendroglioma (AO); Mixed Anaplastic Oligoastrocytoma (AOA) |
Patrick Y. Wen, MD |
2011-12 | PHASE1 |
| NCT01655875 | TERMINATED | Pediatric Acute Myeloblastic Leukemia, Relapsed; Pediatric Acute Lymphoblastic Leukemia, Relapsed |
Emory University |
2012-06 | PHASE1 |
| NCT01373229 | COMPLETED | Leukemia, Lymphocytic, Chronic, B-Cell |
David Rizzieri, MD |
2012-01 | PHASE1 |
| NCT01158118 | COMPLETED | Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Lymphoma, Non-Hodgkin; Hodgkin Disease; Leukemia, Lymphocytic, Chronic, B-Cell; Multiple Myeloma |
Washington University School of Medicine |
2011-04-01 | PHASE2 |
| NCT01236144 | COMPLETED | Acute Myeloid Leukaemia; High Risk Myelodysplastic Syndrome |
Cardiff University |
2011-04 | PHASE1; PHASE2 |
| NCT01318317 | ACTIVE_NOT_RECRUITING | Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Non-Hodgkin Lymphoma |
City of Hope Medical Center |
2011-09-19 | PHASE1; PHASE2 |
| NCT01068301 | COMPLETED | Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Chronic Myeloid Leukemia; Myelodysplastic Syndrome; Non-Hodgkin's Lymphoma |
St. Jude Children's Research Hospital |
2010-05 | PHASE1 |
| NCT01182675 | TERMINATED | Severe Combined Immunodeficiency |
University of California, San Francisco |
2010-08 | PHASE2 |
| NCT01097057 | COMPLETED | Non-Hodgkin Lymphoma |
Fred Hutchinson Cancer Center |
2010-11-09 | PHASE2 |
| NCT01037517 | COMPLETED | Multiple Myeloma; Lymphoma |
CancerCare Manitoba |
2010-01 | PHASE2 |
| NCT01319864 | COMPLETED | Relapsed/Refractory AML; Relapsed/Refractory ALL; Secondary AML/MDS; Acute Leukemia of Ambiguous Lineage; AML; ALL |
Seattle Children's Hospital |
2011-03 | PHASE1 |
| NCT01301963 | TERMINATED | Refractory Multiple Myeloma |
Case Comprehensive Cancer Center |
2011-07 | PHASE3 |
| NCT01802892 | COMPLETED | Transplantation, Stem Cell |
GlaxoSmithKline |
2012-11-02 | PHASE1 |
| NCT01164475 | COMPLETED | Non-Hodgkin's Lymphoma |
Genzyme, a Sanofi Company |
2010-10 | PHASE4 |
| NCT01074060 | COMPLETED | Refractory Multiple Myeloma; Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma |
City of Hope Medical Center |
2010-04 | PHASE1 |
| NCT00906945 | COMPLETED | Leukemia, Myeloid, Acute |
Washington University School of Medicine |
2011-02 | PHASE1; PHASE2 |
| NCT00082329 | COMPLETED | Healthy |
National Heart, Lung, and Blood Institute (NHLBI) |
2004-06-18 | PHASE2 |
| NCT00822770 | COMPLETED | Stem Cell Transplantation; Leukemia |
M.D. Anderson Cancer Center |
2009-01 | PHASE1; PHASE2 |
| NCT00733824 | COMPLETED | Lymphoma, Non-Hodgkin; Hodgkin Disease |
Washington University School of Medicine |
2008-11 | PHASE1; PHASE2 |
| NCT00075335 | COMPLETED | Healthy |
National Heart, Lung, and Blood Institute (NHLBI) |
2004-01 | PHASE2 |
| NCT01095757 | COMPLETED | Myeloma; Lymphoma |
Emory University |
2010-03 | PHASE2 |
| NCT00990054 | COMPLETED | Acute Myeloid Leukemia |
Genzyme, a Sanofi Company |
2009-12 | PHASE1 |
| NCT01579149 | COMPLETED | Healthy Volunteer |
Genzyme, a Sanofi Company |
2011-09 | PHASE1 |
| NCT01220375 | COMPLETED | Myeloma |
Insel Gruppe AG, University Hospital Bern |
2010-04 | PHASE2 |
| NCT01149863 | COMPLETED | Autologous Transplantation |
Emory University |
2010-06 | PHASE2 |
| NCT01042717 | UNKNOWN | Multiple Myeloma; Non-Hodgkins Lymphoma |
Shi, Patricia, M.D. |
2010-02 | |
| NCT00998049 | COMPLETED | Multiple Myeloma; Refractory Multiple Myeloma; Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma |
Mayo Clinic |
2009-12 | PHASE2 |
| NCT01225419 | COMPLETED | Children Cancer, Solid Tumor |
University Hospital, Clermont-Ferrand |
2010-09 | PHASE2 |
| NCT01058993 | COMPLETED | Neutropenia |
University of Washington |
2010-10 | PHASE1 |
| NCT01076270 | TERMINATED | Accelerated Phase Chronic Myelogenous Leukemia; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Atypical Chronic Myeloid Leukemia, BCR-ABL Negative; Blastic Phase Chronic Myelogenous Leukemia; Chronic Phase Chronic Myelogenous Leukemia; de Novo Myelodysplastic Syndromes; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Burkitt Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Grade 1 Follicular Lymphoma; Noncontiguous Stage II Grade 2 Follicular Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Marginal Zone Lymphoma; Noncontiguous Stage II Small Lymphocytic Lymphoma; Previously Treated Myelodysplastic Syndromes; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Hairy Cell Leukemia; Refractory Multiple Myeloma; Relapsing Chronic Myelogenous Leukemia; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes; Splenic Marginal Zone Lymphoma; Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Adult Burkitt Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Diffuse Small Cleaved Cell Lymphoma; Stage III Adult Hodgkin Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Mantle Cell Lymphoma; Stage III Marginal Zone Lymphoma; Stage III Multiple Myeloma; Stage III Small Lymphocytic Lymphoma; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Diffuse Small Cleaved Cell Lymphoma; Stage IV Adult Hodgkin Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Marginal Zone Lymphoma; Stage IV Small Lymphocytic Lymphoma |
Fred Hutchinson Cancer Center |
2010-06 | |
| NCT00914849 | COMPLETED | Hematologic Neoplasms |
Washington University School of Medicine |
2009-08 | PHASE2 |
| NCT00479115 | COMPLETED | Fanconi Anemia |
Children's Hospital Medical Center, Cincinnati |
2007-05 | PHASE1; PHASE2 |
| NCT00694590 | COMPLETED | Chronic Lymphocytic Leukemia (CLL); Small Lymphocytic Lymphoma (SLL) |
Genzyme, a Sanofi Company |
2008-06 | PHASE1 |
| NCT00838357 | COMPLETED | Lymphoma (Non-Hodgkin's Lymphoma); Hodgkin's Disease or Multiple Myeloma; Front Line Mobilization; Transplantation |
Genzyme, a Sanofi Company |
2008-09 | PHASE3 |
| NCT00901225 | COMPLETED | Multiple Myeloma; Non-Hodgkins Lymphoma; Hodgkins Disease |
Duke University |
2009-05 | PHASE2 |
| NCT01027923 | TERMINATED | Leukemia, Myeloid, Acute |
Washington University School of Medicine |
2010-05 | PHASE1 |
| NCT00512252 | COMPLETED | Leukemia, Myeloid, Acute |
Washington University School of Medicine |
2007-07 | PHASE1; PHASE2 |
| NCT00396331 | COMPLETED | Autologous Stem Cell Transplantation |
Genzyme, a Sanofi Company |
2005-10 | PHASE2 |
| NCT00241358 | COMPLETED | Leukemia, Myeloid, Acute; Leukemia, Myelogenous, Chronic; Leukemia, Lymphoblastic, Acute; Lymphocytic Leukemia, Chronic; Myelodysplastic Syndromes; Multiple Myeloma; Lymphoma, Non-Hodgkin; Hodgkin Disease |
Washington University School of Medicine |
2004-05 | PHASE1; PHASE2 |
| NCT00444912 | COMPLETED | Non-Hodgkin Lymphoma; Hodgkin Disease |
Genzyme, a Sanofi Company |
2006-02 | PHASE2 |
| NCT00665314 | COMPLETED | Lymphoma; Non Hodgkin's Lymphoma; Hodgkin's Disease; Multiple Myeloma |
Genzyme, a Sanofi Company |
2007-11 | PHASE2 |
| NCT00396266 | COMPLETED | Multiple Myeloma; Lymphoma, Non-Hodgkin |
Genzyme, a Sanofi Company |
2005-01 | PHASE2 |
| NCT00445302 | COMPLETED | Renal Impairment |
Genzyme, a Sanofi Company |
2006-01 | PHASE1 |
| NCT00396383 | TERMINATED | Multiple Myeloma |
Genzyme, a Sanofi Company |
2004-11 | PHASE2 |
| NCT00322842 | COMPLETED | Lymphoma, Non-Hodgkin; Multiple Myeloma |
Genzyme, a Sanofi Company |
2004-09 | PHASE2 |
| NCT00396201 | COMPLETED | Hodgkin's Disease |
Genzyme, a Sanofi Company |
2004-11 | PHASE2 |
| NCT00103662 | COMPLETED | Multiple Myeloma |
Genzyme, a Sanofi Company |
2005-01 | PHASE3 |
| NCT00103610 | COMPLETED | Lymphoma, Non-Hodgkin |
Genzyme, a Sanofi Company |
2005-01 | PHASE3 |
| NCT00322387 | COMPLETED | Lymphoma, Non-Hodgkin; Multiple Myeloma |
Genzyme, a Sanofi Company |
2004-04 | PHASE2 |
| NCT00322491 | COMPLETED | Lymphoma, Non-Hodgkin; Multiple Myeloma |
Genzyme, a Sanofi Company |
2004-03 | PHASE2 |
| NCT00395967 | TERMINATED | Multiple Myeloma; Lymphoma, Non-Hodgkin's |
Genzyme, a Sanofi Company |
2005-04 | PHASE2 |
| NCT00396968 | WITHDRAWN | Acute Myelogenous Leukemia; Myelodysplastic Syndromes |
Genzyme, a Sanofi Company |
PHASE1; PHASE2 |
(data from https://clinicaltrials.gov, updated on 2026-09-03)
Check the
AMD3100 (Plerixafor)
product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.
Mechanism and Biochemical Profile
Appendix RUO and cGMP Quality Standards
| Quality Dimension | RUO (Research Use Only) | cGMP (Current Good Manufacturing Practice) |
|---|---|---|
| Clinical Applicability | Prohibited in human clinical trials or medical diagnostics. | Mandatory for human clinical trials (Phase I–III) and therapies. |
| Regulatory Status | Non-regulated grade; exempt from drug manufacturing laws. | Legally enforced by health authorities (e.g., FDA, EMA, NMPA). |
| Facility Environment | Unclassified analytical or research laboratories. | Validated Cleanrooms (ISO Class 5–8) with continuous monitoring. |
| Quality Control | Basic purity and activity testing. | Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma). |
| Process Validation | Basic equipment calibration; no process validation required. | Full qualification (IQ/OQ/PQ) and complete batch records. |
| Quality Assurance | Vendor self-declared without required formal QMS. | Mandatory QA/QC unit, Change Control, CAPA, and vendor audits. |
| Regulatory Impact | High risk of IND rejection if used as a critical raw material. | Required for IND/NDA filings, supported by Drug Master Files (DMF). |
Footnotes
Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).
- AMD3100 (Plerixafor) Mechanism of Action: CXCR4 Inhibition in Immune Cell Research
- AMD3100 (Plerixafor): Selectivity & Specificity
- AMD3100 (Plerixafor) Working Concentration | Cell Culture | Treatment
- AMD3100 (Plerixafor) Solubility in DMSO
- AMD3100 (Plerixafor) Stock Solution
- AMD3100 (Plerixafor) Storage
- AMD3100 (Plerixafor) Stability
- AMD3100 (Plerixafor) Combination Database
- AMD3100 (Plerixafor) Molecular Weight
- AMD3100 (Plerixafor) SMILES
- AMD3100 (Plerixafor) CAS Number
- AMD3100 (Plerixafor) Chemical Structure (2D and 3D)
- AMD3100 (Plerixafor) IC50 for Cell-based and Cell-free Assays
- AMD3100 (Plerixafor) Sigma (1545135)? Try a better option.
- AMD3100 (Plerixafor) MedChemExpress (HY-10046)? Try a better option.
- AMD3100 (Plerixafor) Cayman (35579)? Try a better option.
- AMD3100 (Plerixafor) APExBIO (A2025)? Try a better option.
- AMD3100 (Plerixafor) SDS｜MSDS
Note: Technical data last updated: Sep 1, 2026.